Research programme: secreted protein therapeutics - ARCA biopharma/Kyowa Hakko Kirin

Drug Profile

Research programme: secreted protein therapeutics - ARCA biopharma/Kyowa Hakko Kirin

Alternative Names: Wnt therapeutics program

Latest Information Update: 08 Oct 2012

Price : $50

At a glance

  • Originator Kirin Brewery; Nuvelo
  • Developer ARCA biopharma Inc
  • Class Proteins
  • Mechanism of Action Intercellular signalling peptide and protein stimulants; Wnt signalling pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Inflammatory bowel diseases; Mucositis

Most Recent Events

  • 05 Oct 2012 Discontinued - Preclinical for Cancer in USA (IV)
  • 05 Oct 2012 Discontinued - Preclinical for Inflammatory bowel disease in USA (IV)
  • 05 Oct 2012 Discontinued - Preclinical for Mucositis in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top